| Symbol | ACAD |
|---|---|
| Name | ACADIA PHARMACEUTICALS INC |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Pharmaceutical Preparations |
| Address | 12830 EL CAMINO REAL, SAN DIEGO, CA 92130 |
| Telephone | 858-558-2871 |
| Fax | — |
| — | |
| Website | https://www.acadia.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001070494 |
| Description | Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinsons, Alzheimers, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The companys patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology. Additional info from NASDAQ: |
Riassunto: La Commissione europea approva DAYBU® (trofinetide) come primo e unico trattamento dei sintomi neuro-comportamentali della sindrome di Rett nell'Unione Europea
Read moreLa Commission européenne a approuvé DAYBU® (trofinetide), le premier et unique traitement des symptômes neurocomportementaux du syndrome de Rett au sein de l’Union européenne
Read moreEuropäische Kommission erteilt Zulassung für DAYBU® (Trofinetid) als erste und einzige Therapie für neurobehaviorale Symptome des Rett-Syndroms in der Europäischen Union
Read moreDe Europese Commissie keurt DAYBU® (trofinetide) goed als eerste en enige behandeling voor neurologische gedragssymptomen van het Rett-syndroom in de Europese Unie
Read moreLa Comisión Europea aprueba DAYBU® (trofinetida) como el primer y único tratamiento para los síntomas neuroconductuales del Síndrome de Rett en la Unión Europea
Read moreEuropean Commission Approves DAYBU® (trofinetide) as the First and Only Treatment for Neurobehavioral Symptoms of Rett Syndrome in the European Union
Read moreSchneyer Mark C. 🟡 adjusted position in 20.1K shares (2 derivative) of ACADIA PHARMACEUTICALS INC (ACAD) at $29.34 ($1.3M) Transaction Date: Aug 05, 2026 | Filing ID: 000008
Read moreNew Form SCHEDULE 13G - ACADIA PHARMACEUTICALS INC <b>Filed:</b> 2026-08-07 <b>AccNo:</b> 0000093751-26-000400 <b>Size:</b> 8 KB
Read moreAcadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimers Disease Psychosis
Read more